← Back to Clinical Trials
Recruiting NCT06856694

NCT06856694 RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06856694
Status Recruiting
Phase
Sponsor Cedars-Sinai Medical Center
Condition Prostate Cancer
Study Type INTERVENTIONAL
Enrollment 283 participants
Start Date 2025-10-22
Primary Completion 2029-05

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
NLP+AI Report

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 283 participants in total. It began in 2025-10-22 with a primary completion date of 2029-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the research is to assess the impact of a natural language processing + artificial intelligence (NLP+AI)-based risk communication feedback system to improve quality of risk communication of key tradeoffs during prostate cancer consultations among physicians and to improve patient decision making. In this cluster randomized trial, an evaluable 259 patients with newly diagnosed clinically localized prostate cancer will be cluster randomized within an evaluable 24 physicians to: 1. a control arm, in which patients will receive standard of care treatment consultations along with AUA-endorsed educational materials on treatment risks and benefits (for patients) and on SDM (for physicians) or 2. an experimental arm, in which patients and participating physicians will receive NLP+AI-based feedback on what was said about key tradeoffs within approximately 72 hours of the consultation to assist with decision making. Physicians will additionally be provided with grading of their risk communication for each visit based on an a priori defined framework for quality of risk communication and recommendations for improvement. In both study arms, there will be an audio-recorded follow-up phone or video call between the physician and patient to allow for further discussion of risk and clarifying any areas of ambiguity, which will be qualitatively analyzed to see if areas of poor communication were rectified. After the follow-up phone call, patients and participating physicians will be asked to complete a very brief survey about their experience. The study plans to test whether receiving NLP+AI-based feedback improves decisional conflict, shared decision making, and appropriateness of treatment choice over the standard of care in patients undergoing treatment consultations for prostate cancer. Study staff will also test whether providing feedback and grading of risk communication to physicians affects quality of physician risk communication, since providing feedback will promote more accountability for the quality of information provided to patients. The study will also analyze data from the control arm of the randomized controlled trial to understand variation in risk communication of key tradeoffs in relevant subgroups of tumor risk (low-, intermediate-, and high-risk), provider specialty (Urology, Radiation Oncology, Medical Oncology), and patient sociodemographics.

Eligibility Criteria

Inclusion Criteria: Physician Inclusion Criteria (1) Physicians who typically counsel prostate cancer patients (Urology, Radiation Oncology, Medical Oncology) Patient Inclusion Criteria 1. Patients undergoing initial treatment consultation for clinically localized prostate cancer; 2. Patients with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy; 3. Ability to read and write in English. Patient Exclusion Criteria: 1. Under 18 years of age; 2. Subjects with difficulty communicating or dementia; 3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English; 4. Patients with locally advanced or metastatic prostate cancer; 5. Patients who have already been treated for clinically localized prostate cancer.

Contact & Investigator

Central Contact

Timothy Daskivich, MD

✉ Timothy.Daskivich@cshs.org

📞 310-423-4700

Frequently Asked Questions

Who can join the NCT06856694 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06856694 currently recruiting?

Yes, NCT06856694 is actively recruiting participants. Contact the research team at Timothy.Daskivich@cshs.org for enrollment information.

Where is the NCT06856694 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT06856694 clinical trial?

NCT06856694 is sponsored by Cedars-Sinai Medical Center. The trial plans to enroll 283 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology